Literature DB >> 8675742

OCT embedded sections of pathological specimens as a source of high quality RNA for reverse transcriptase/polymerase chain reaction.

J A Irving1, G Cain, A Parr, M Howard, B Angus, A R Cattan.   

Abstract

OCT embedded cryostat sections of stored pathological specimens of non-Hodgkin's lymphoma were used to provide RNA. After reverse transcription to produce cDNA, the polymerase chain reaction was performed with primers for standard and variant forms of the CD44 molecule. Using Southern transfer and hybridisation with a probe specific for exon 4 of the CD44 gene, both standard and variant forms were visualised by autoradiography. This method was shown to be applicable to other gene products by using primers specific for the abl and bcr genes. This technique permits retrospective analysis of RNA from small amounts of stored pathological samples.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675742      PMCID: PMC500411          DOI: 10.1136/jcp.49.3.258

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

Review 1.  CD44 isoforms during differentiation and development.

Authors:  P Ruiz; C Schwärzler; U Günthert
Journal:  Bioessays       Date:  1995-01       Impact factor: 4.345

Review 2.  CD44 and its role in tumour progression and metastasis.

Authors:  J A East; I R Hart
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

3.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

4.  Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.

Authors:  N C Cross; L Feng; J Bungey; J M Goldman
Journal:  Leuk Lymphoma       Date:  1993

5.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.

Authors:  N C Cross; J V Melo; L Feng; J M Goldman
Journal:  Leukemia       Date:  1994-01       Impact factor: 11.528

7.  CD44 variant exon epitopes in primary breast cancer and length of survival.

Authors:  M Kaufmann; K H Heider; H P Sinn; G von Minckwitz; H Ponta; P Herrlich
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

8.  Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.

Authors:  P Dall; K H Heider; H P Sinn; P Skroch-Angel; G Adolf; M Kaufmann; P Herrlich; H Ponta
Journal:  Int J Cancer       Date:  1995-02-08       Impact factor: 7.396

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Expression and modulation of CD44 variant isoforms in humans.

Authors:  C R Mackay; H J Terpe; R Stauder; W L Marston; H Stark; U Günthert
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

  10 in total
  2 in total

1.  The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy.

Authors:  J A Irving; G Cain; M Howard; B Angus; P R Taylor; A R Cattan
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Comparative analysis of cytokine transcript profiles within mediastinal lymph node compartments of pigs after infection with porcine reproductive and respiratory syndrome genotype 1 strains differing in pathogenicity.

Authors:  Obdulio García-Nicolás; Rubén S Rosales; Francisco J Pallarés; David Risco; Juan J Quereda; Simon P Graham; Jean-Pierre Frossard; Sophie B Morgan; Falko Steinbach; Trevor W Drew; Tony S Strickland; Francisco J Salguero
Journal:  Vet Res       Date:  2015-03-19       Impact factor: 3.683

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.